Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020

Silvia Fernández-Martín*, Mónica López-Peña, Fernando Muñoz, María Permuy and Antonio González-Cantalapiedra

Abstract

Bisphosphonates have been proposed as possible disease-modifying drugs in osteoarthritis. However, the evidence of their efficacy is poor and their outcomes presented a great heterogeneity. Therefore, the aim of this study is to systematically review the main effects of bisphosphonate use on synovial joint tissues and biochemical markers in preclinical studies over the past two decades (2000–2020). Three databases (Pubmed, Scopus, and Web of Science) were searched, and after screening, twenty-six studies with five different types of bisphosphonates were included in the review. The animal model selected, the type of bisphosphonate used, the therapy duration, and the main effects of individual drugs on synovial tissues were evaluated. Additionally, the quality and risk of bias assessments were performed using the Animals in Research Reporting In Vivo Experiments guidelines and the Systematic Review Centre for Laboratory animal Experimentation tool. Studies showed high variability in experimental designs. Consequently, the comparison of the findings in order to draw specific conclusions about the effectiveness of the drugs is complicated. However, the results of this systematic review suggested that bisphosphonates seemed to reduce the osteoarthritic changes in a dose-dependent manner showing better chondroprotective effects at high doses. Besides, a time-dependent efficacy was also detected in terms of cartilage status. One can conclude that the disease stage of the time-point of treatment initiation may constitute a key factor in the antiresorptive drug efficacy. Generally, we noted that bisphosphonate administration seemed to show positive subchondral bone conservation and fewer biomarker alterations. However, they did not appear to suppress the osteophyte development and their chondroprotective effect is highly variable among the studies. Bisphosphonates appeared to show a positive anti-inflammatory effect on the synovial membrane. However, only a few included publications were focused on their investigation. Regarding the therapy duration, there is a significant lack of evidence on evaluating their effectiveness in preclinical long-term studies and further experimental studies may be needed to examine the pharmacological response in these circumstances. This systematic review might help to clarify the efficacy of bisphosphonates and their function as disease-modifying treatments in osteoarthritis.

Keywords: Osteoarthritis, Bisphosphonates, Disease-modifying drugs, Animal models, Subchondral bone, Biochemical markers

* Correspondence: silvia.fernandez.martin@usc.es
Anatomy, Animal Production and Veterinary Clinical Sciences Department, Veterinary Faculty, Universidad de Santiago de Compostela, Campus Universitario s/n, 27002 Lugo, Spain

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

Osteoarthritis (OA) is thought to be the most prevalent chronic degenerative joint disease in animals and humans, leading to pain, stiffness, and disability. Structural changes include osteophyte formation, synovial inflammation, bone remodeling, and pathological changes in cartilage and menisci, among others [1]. The physical impact and the economic burden of this musculoskeletal disease are immense, affecting approximately 15% of the human global population (>50% of the aging population over 60 years of age) [2, 3] and being ranked the 12th major cause of global disability in 2016 [4]. Regarding veterinary medicine, it is highly prevalent in dogs and causes noticeable signs of pain and lameness [5]. However, the current information on the prevalence of canine OA is limited and the reported values are widely variable [6]. Additionally, contrary to humans, there is little epidemiological data available on this disease in the different animal species [7].

At present, there are no identifiable disease-modifying treatments for OA; thus, its management is an enormous challenge. Scientific community has been working for years on the development of systemic drugs, which can slow down or prevent the articular cartilage damage and subchondral bone changes, as well as reduce the pain and other symptoms. It has been suggested that the status of the subchondral bone compartment should be a potential target in OA [8, 9]. In relation to this, antiresorptive drugs have been studied for their possible beneficial effects on decreasing bone remodeling and improving bone mineralization and trabecular microarchitecture. Within the available options, bisphosphonates (BPs) have been considered to have a positive impact on articular cartilage and periarticular bone changes by inhibiting bone-resorption activity [10]. However, their mechanism of action and effectiveness in OA is not yet clear.

To better understand the pathophysiology and evolution of this illness, many animal models have been developed as an attempt to mimic the natural human disease. The in vivo preclinical animal studies play a key role in the study of the therapeutic drug efficacy, allowing the histopathological analysis of affected joints at different disease stages [11, 12]. Additionally, recent advances in diagnostic techniques, such as new imaging modalities and biochemical assessments, have proven useful to improve our understanding of the disease, allowing us to evaluate all essential joint tissue components [11]. As previously mentioned, BPs have been proposed as possible disease-modifying drugs in OA. However, both in preclinical and clinical studies, research findings are inconsistent. Some systematic reviews of randomized controlled trials were conducted as an attempt to clarify the effect of BPs in human OA. All of them were in agreement that there was an important heterogeneity across the studies analyzed. They mainly concluded that BPs showed limited evidence for pain control or symptomatic clinical relief, and additionally, no radiographic changes were observed [13–15]. Regarding experimental preclinical studies with animal models, there are currently no updated systematic reviews evaluating the impact of BPs on structural OA changes. Consequently, we consider it may be of interest to elucidate their function as possible disease-modifying treatments.

This systematic review will overview the efficacy of commonly used bisphosphonates for OA treatment in experimental animal models. The aim of this study is to record and categorize the outcome measures on synovial joint tissues and biochemical markers in preclinical studies by systematically reviewing the last two decades of peer-reviewed publications on OA.

**Methods**

**Protocol and search strategy**

This systematic review was conducted and reported according to the formal PRISMA guidelines (“Preferred Reporting Items for Systematic Reviews and Meta-Analyses”) [16, 17]. The search strategy was performed in the following online databases: PubMed, Scopus, and Web of Science (WOS). The studies were identified using the combination terms: “osteoarthritis,” “bisphosphonates,” and “animal models” as keywords.

**Inclusion and exclusion criteria**

The inclusion criteria were as follows:

- Experimental studies in animal models of OA in which the effect of bisphosphonate drugs on biochemical markers and knee synovial joint tissues such as cartilage, synovial membrane, and subchondral bone were assessed, through gross, histology, biochemical, and/or imaging techniques.
- Studies published in internationally peer-reviewed journals between 2000 and June 2020.
- Articles published in English.
- Accessible by authors through Internet searching or institutional access.

The exclusion criteria were articles written in other languages, reviews, book chapters, in vitro studies, clinical trials, and reports in which none of the outcomes of interest were analyzed.

**Study selection and data extraction**

At first, titles and abstracts were selected through an online search for inclusion. Next, the screening process was conducted using the inclusion and exclusion criteria.
Subsequently, the full text of articles assessed for eligibility was screened and duplicates were removed. Assessments were performed by a single author (SFM) with team consensus by all authors. The authors extracted the following information from each paper included: animal characteristics (species, gender, and age), number of animals, osteoarthritis animal model, drug therapy (dosage, frequency, and duration), baseline, methods of evaluation, and main results. The outcome measures reported in each publication were recorded and categorized for comparison.

Additionally, the studies were grouped according to the duration of the treatments, into short-term treatments (≤2 months), intermediate-term treatments (between 2 and 6 months), and long-term treatments (≥6 months). In studies where the drug administration was made on different specific days, we selected the longest term.

Lastly, we performed a qualitative synthesis of the main findings, summarizing the effects of the BPs evaluated on structural joint tissues (cartilage, subchondral bone, and synovial membrane), osteocyte development, and biochemical markers. We classified the outcomes as positive effect (+), negative effect or no effect (−), and unclear effect (?). The latter was determined when contradictory outcomes were observed or when we had an initial positive response, but not maintainable over time. Also, we marked as not included (×) when the parameters were not evaluated.

Risk of bias and quality assessments
Two independent authors (SFM and AGC) performed the quality and risk of bias assessments, and any discrepancies were resolved with team consensus by all authors. We systematically analyzed the quality of the included in vivo preclinical studies using the Animals in Research Reporting In Vivo Experiments (ARRIVE) guidelines [18]. For this purpose, we checked each item of the 20 included in this checklist and responded with “yes” if the publication complies, “no” if it does not, and “unclear” if the details were not completed in all sub-items.

The risk of bias was assessed using the Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) tool for animal studies [19], an adapted version of the Cochrane Risk of Bias tool for randomized controlled trials, where additional criteria specific to animal studies were added. The risk-of-bias tool contains 10 entries with specific signaling questions. In order to assign a judgment of low, high, or unclear risk of bias to each item, when responding the signaling questions with “yes” indicated low risk of bias, “no” indicated high risk of bias and “unclear” if insufficient details were reported to assess the risk of bias properly. The entries were classified as high risk of bias if one or more signaling questions were not met and at unclear risk of bias if one or more were partly satisfied.

Results
Study selection
The literature search resulted in 103 potentially eligible publications, identified and screened in the initial search. Forty-seven articles were retrieved using PubMed www.pubmed.com, 17 articles using Scopus www.scopus.com, and 39 articles using Web of Science www.webofscience.com. In addition, 3 articles were identified through other resources. The remaining publications (n = 106) were screened, and after the evaluation of the inclusion and exclusion criteria, 52 records were excluded. After screening, 54 individual studies were identified as potentially eligible and checked in full-text. Out of them, 16 full-text articles were excluded and 12 duplicate articles were removed. Finally, a total of 26 articles were found suitable to be included in the present systematic review. They dated from 2002 to 2017 and were found in 13 journals. The study selection process can be found in Fig. 1.

Study characteristics and results of individual studies
Main data extraction from the included articles is shown in Table 1. The results are explained below in detail, based on the animal model selected, the type of bisphosphonate used, the therapy duration, and finally, the main drug effect observed.

Animals and osteoarthritis models
Preclinical studies included healthy animals of both sexes and were performed in rabbits (9 out of 26; 34.6%) and rats (9 out of 26; 34.6%), followed by mice (3 out of 26; 11.5%), guinea pigs (2 out of 26, 7.8%), and dogs (3 out of 26; 11.5%). In this review, in the majority of the studies that included dog and rabbit models, OA was surgically induced by anterior cruciate ligament transection (ACLT) and/or medial meniscectomy (MMT) [20–27, 43–45]. Only one study in rabbits used intraarticular injection of chymopapain for chemically-induced OA [28]. Regarding experimental rodents, several animal models were used for mimicking OA such as surgically induced models through ACLT [29, 37], MMT [30, 33], or knee triad injury (KTI) [35]; chemically-induced models by an injection of monosodium iodoacetate (MIA) [32, 36, 40], non-invasive loading models [38, 39], and spontaneous-models [31]. Lastly, we included two studies employing guinea pigs as spontaneous OA knee models [41, 42].

Types of bisphosphonates
Five types of bisphosphonates were analyzed. The most common type was alendronate, studied in 11 articles:
two in rabbits [23, 24], five in rats [31–33, 35, 37], three in mice [38–40], and one in guinea pigs [42]. It was followed by zoledronic acid with 7 articles: three in rabbits [20, 21, 28], three in rats [29, 30, 36], and one in dogs [43], and risedronate with 6 studies: four in rabbits [22, 25–27], one in rats [35], and one in guinea pigs [41]. Two studies in dogs evaluated the effect of tiludronate [44, 45], and only one study in rats focused on the effect of pamidronate [34]. It should also be noted that in one of the studies [35], the effect of two types of BPs (alendronate and risedronate) was evaluated.

**Therapy duration**

The great majority of the studies included in this review were based on short periods of treatment administration, with ≤2 months of BP therapy (n = 17). Regarding intermediate periods of time, we identified 7 articles, with therapy durations between 2.5 and 4.5 months. Finally, we only identified 2 publications with drug therapies ≥6 months, one which evaluated the effect of risedronate for 6 months in guinea pigs [41], and another which used zoledronic acid for 1 year in experimental dogs [43] (Table 2).

**Synthesis of main outcomes of the effect of bisphosphonates**

Preclinical studies were evaluated based on the effect of BPs on cartilage, subchondral bone, synovial membrane, osteophyte formation, and biochemical OA markers (Table 3). The most studied parameter was the cartilage status, assessed in all publications (n = 26), followed by the subchondral bone (n = 19), the biochemical analysis (n = 13), and the osteophyte development (n = 11). The synovial assessments (n = 4) are ranked last.

Overall, the cartilage was typically evaluated through gross and histologic analysis. It is seems that the zoledronic acid showed the greatest chondroprotective effect, with only one article (1 out of 7) where the drug failed to prevent or correct cartilage deterioration [30]. The use of alendronate exhibited positive effects in more

---

**Table 2**

| Treatment          | Studies Included | Therapy Duration |
|--------------------|------------------|------------------|
| Alendronate        | 2                | ≤2 months        |
| Risedronate        | 4                | 2.5–4.5 months   |
| Zoledronic acid    | 1                | ≥6 months        |

**Table 3**

| Outcome                | Studies Included |
|------------------------|------------------|
| Cartilage status       | 26               |
| Subchondral bone       | 19               |
| Biochemical analysis   | 13               |
| Osteophyte development | 11               |
| References | Animal model (n) | OA model and site | Therapy: dosage, frequency and duration | Start point | Follow-up and evaluations | Main results |
|------------|----------------|------------------|----------------------------------------|-------------|--------------------------|--------------|
| She et al. [20] | New Zealand Rabbit; Male 5–7 monthsold (32) | Surgically-induced OA; ACLT Knee | Zoledronic acid (250, 50 and 10 μg/kg i.v.) Once post-surgery | 0 days | 0, 4, and 8 weeks | X-ray absorptiometry scanner (BMD) and MRI (cartilage thickness). Histology of cartilage (Mankin score system) ZOL improved the microstructure and reduced the degeneration of articular cartilage in a dose-dependent manner, showing better chondroprotective effects at the high doses. On subchondral bone, ZOL ↑ BMD. |
| Lampropoulou-Adamidou et al. [21] | New Zealand Rabbit; Male 25 weeksold (18) | Surgically-induced OA; ACLT Knee | Zoledronic acid (0.6 mg/kg i.v.) On day 1, 15, and 29 | 1 day | 8 weeks | Macroscopic evaluation Histology of cartilage (modified Mankin score) Macrocopically ZOL group had significantly milder ulcerations, cartilage softening and fibrillation. Microscopically ZOL showed chondroprotective effect. |
| Permuy et al. [22] | New Zealand Rabbit; Female 6–7 months old (32) | Surgically-induced OA; ACLT and partial MMT; Knee | Glucosamine (21.5 mg/kg day oral) +/- or Risedronate (0.07 mg/kg/day oral) 8 weeks | 3 weeks | 11 weeks | Histology of cartilage and synovial (OARSI score), Histomorphometric evaluation and μ-CT (BV/TV, Tb.Th, Tb.Sp, Tb.N, Tb.Pf) RIS treatment alone or in combination showed improves cartilage swelling, superficial fibrillation and less inflammatory changes in the synovial membrane. On subchondral bone, RIS modify the orientation of trabecular lattice (↑ Tb.Sp and ↓ Tb.N) |
| Shirai et al. [23] | New Zealand Rabbit; Female 9 months old (30) | Surgically-induced OA; ACLT Knee | Alendronate (0.14 mg/kg/ weekly s.c.) 2, 4 or 12 weeks | 0 days | 2, 4, or 12 weeks | Histology of cartilage (Mankin score system) μ-CT (BV/TV), subchondral bone plate thickness and osteophyte development. Immunohistochemistry (MMP13, IL-1β, COLX, VEGF and RANKL) ALN showed chondroprotective effect and prevented periarticular bone loss. Immunohistochemical analysis showed that ALN suppressed the expression of MMP13, IL-1β, COLX, VEGF, and RANKL in OA cartilage. |
| Zhang et al. [24] | Japanese Rabbit; Male 10 weeks old (30) | Surgically-induced OA; ACLT Knee | Alendronate (10 μg/kg/day s.c.) 56 days | 4 days | 60 days | Histology of cartilage (Mankin score system) X-ray absorptiometry scanner (BMD) and histomorphometric assays (BV/TV, Tb.Th, Tb.N, Tb.Sp), Immunohistochemistry (BMP-2 and MMP-13) ALN treatment reduced cartilage lesions and delayed the cartilage degeneration. Significantly suppressed subchondral bone resorption (↑ BMD, BV/TV, Tb.Th, and Tb.N). Also, showed chondroprotective role in immunohistochemistry assays (↑ BMP-2 and ↓ MMP-13). |
| MacNeil et al. [25] | New Zealand Rabbit; Female Mature (18) | Surgically-induced OA; ACLT Knee | Risedronate (0.01 mg/kg/day s.c.) 6 weeks | ? | 6 weeks | μ-CT (BV/TV, BS/BV, Tb.N, Tb.Th, Tb.Sp, Conn.D, Ct.Th, BMD) RIS group exhibited areas of developing osteophytes. Cartilage surface showed only focal roughening. RIS animals showed periarticular bone conservation (BV/TV, Ct.Th) |
| Doschak et al. [26] | New Zealand Rabbit 1 year old (28) | Surgically-induced OA; ACLT Knee | Risedronate (0.01 mg/kg/daily s.c.) 6 weeks | ? | 6 or 14 weeks | Histology of cartilage (Modified Mankin score system) μ-CT (laxity and volume of the MCL) RIS treatment conserved periarticular bone and improved MCL-complex laxity. However, showed the higher scores on the modified Mankin scale. |
| Doschack et al. [27] | New Zealand Rabbit 1 year old (30) | Surgically-induced OA; ACLT Knee | Risedronate (0.01 mg/kg/daily s.c.) 6 weeks | ? | 6 weeks | Histology of cartilage (Modified Mankin score system). X-ray absorptiometry scanner (BMD) Biochemical of periarticular bone RIS treatment conserved periarticular BMD and ligament mechanical properties. RIS did not have de capacity to supress osteophytosis nor early cartilage signs of degradation. |
| Muehleman | New | Chemically | Zoledronic acid (10 μg/kg/3) | 1 day | 28 or 56 days | ZOL treated animals displayed |
| References | Animal model (n) | OA model and site | Therapy: dosage, frequency and duration | Start point* | Follow-up and evaluations | Main results |
|------------|-----------------|-------------------|----------------------------------------|-------------|----------------------------|-------------|
| et al. [28] Zealand Rabbit; Male Adolescent (58) | induced OA: Chymopapain Knee | times per week s.c. 8, 28; or 56 days | Macroscopic evaluation Histology of cartilage and PG content Urine samples (collagen cross-links) | a significantly lower degree of grossly and histologically cartilage degeneration. Urinary levels of collagen cross-links were higher in untreated animals. |
| Cinar et al. [29] Wistar Rat Male Adult (48) | Surgically induced OA: ACLT Knee | Zoledronic acid (10 μg/kg/ weekly intra-articular) 4 days, 3 or 6 weeks | 0 days | ZOL intra-articular administration showed significant reduced synovitis and partially chondroprotective effect, although did not completely prevent cartilage damage. |
| Bagn et al. [30] Lewis Rat Male 4 month old (48) | Surgically induced OA: MM Knee | Zoledronic acid (100 μg/kg/2 times per week s.c.) PTH (40 μg/kg/5 times per week s.c.) 10 weeks | 0 days | ZOL and PTH improved subchondral bone mas (TbB/TV, TBN and TbTh), but both treatments failed to prevent or correct cartilage deterioration, thickening of the subchondral bone plate, osteophyte formation nor the mechanical incapacity. ZOL ↓CTX-II level serum. |
| Zhu et al. [31] Sprague-Dawley Rat; Female 7 months-old (78) | Spontaneously model: Menopause-OA (OVX) Knee | Alendronate (30 μg/kg/twice weekly s.c.) 2, 10 or 18 weeks | 0 or 8 weeks | Early ALN treatment prevented both subchondral bone loss and cartilage surface erosion. Late ALN treatment was able to inhibit subchondral bone loss but did not reverse cartilage erosion. ALN ↓MMP-13 and MMP-9. |
| Mohan et al. [32] Wistar Rat Male 8 weeks-old (84) | Chemically induced OA: MIA Knee | Alendronate (15 μg/kg/2 times per week s.c.) Pre-emptive: day 0 to 14; early: day 14 to 42; delayed: day 42 to end of week 10 | 0, 14, or 42 days | Pre-emptive ALN treatment preserved subchondral bone, decreased bone turnover and had moderate effects on cartilage degradation. Early and delayed ALN treatments prevented bone loss and decreased bone turnover, but had no significant effect on cartilage degradation. |
| Panahafir et al. [33] Sprague-Dawley Rat; Female 6 weeks-old (15) | Surgically induced OA: MMT Knee | Alendronate (0.12 mg/kg/ twice weekly s.c.) 8 weeks | 1 day | ALN treatment inhibited osteophyte development and were more cartilaginous (BMD). Also, ALN showed reduced degeneration of the cartilage. |
| Koh et al. [34] Sprague-Dawley Rat; Female 6 months-old (30) | Chemically induced OA: MIA Knee | Pamidronate (3 mg/kg/ weekly s.c.) 8 weeks | 8 weeks earlier | PAM treatment showed less trabecular bone changes and cartilage damage |
| Jones et al. [35] Sprague-Dawley Rat; Female 6 weeks old (58) | Surgically induced OA: KTI Knee | Alendronate (0.12 mg/kg/2 times per week s.c.) Risedronate (0.06 mg/kg/2 times per week s.c.) | 1 day | Treatments with BPs showed reduced levels of trabecular bone loss (BTV). ALN reduced bony osteophyte development, but RIS did not positively impact. Histologic analysis confirmed the |
### Table 1 Characteristics of included preclinical studies (Continued)

| References | Animal model (n) | OA model and site | Therapy: dosage, frequency and duration | Start point | Follow-up and evaluations | Main results |
|------------|-----------------|------------------|-----------------------------------------|-------------|--------------------------|--------------|
| Strassle et al. [36] | Sprague-Dawley Rat; Male 8 weeks-old (195) | Chemically induced OA: MIA Knee | Zoledronic acid (10, 30, or 100 μg/kg/every third day s.c.): Pre-emptive: day 1 to 21; early: day 14 to 21 or 35; delayed chronic: day 21 to 35; sub-chronic: 28 to 35 | 1, 14, 21, or 28 days | 5 or 22 days | ZOL high-dose group resulted in a chondroprotective effect of both BPs. |
| Hayami et al. [37] | Sprague-Dawley Rat; Male 20 weeks-old (95) | Surgically induced OA: ACLT Knee | Alendronate (15 or 120 μg/kg/2 times per week s.c.): 2 or 10 weeks | 3 days | 2 or 10 weeks | ALN showed chondroprotective effect, suppressed subchondral bone resorption and reduced osteophyte area (dose-dependent manner). ↓MMP-13, MMP-9 and TGFβ. |
| Adebayo et al. [38] | C57BL/6 (B6) and FVB/NJ (FVB) Mice Male 26 week old | Non-invasive loading OA: CACTC Knee | Alendronate (26 μg/kg/day i.p.): 1, 2 or 6 weeks | 0 days | 1, 2, or 6 weeks | ALN treatment inhibited bone remodeling and, in B6 mice cartilage pathology was exacerbated, while in FVB mice cartilage loss was protected. ALN inhibited osteophyte maturation, but did not affect osteophyte size. |
| Khorasani et al. [39] | C57BL/6 N Mouse Female 10 weeks old (90) | Non-invasive loading OA: Tibial compression overload Knee | Alendronate (40 or 100 μg/kg/twice weekly s.c.): 7, 14 or 56 days | 0 days | 7, 14 or 56 days | High-dose ALN of treatment was able to prevent early trabecular bone loss and cartilage degeneration, but was not able to inhibit osteophyte formation, nor was it able to mitigate long-term degeneration. ALN ↓CTX-I serum |
| Sniekers et al. [40] | C3H/HeJ Mouse Female 12 weeks old (32) | Menopause-related OA (OVX) and chemically-induced OA: MIA Knee | Estradiol (12 μg/day s.c. implant): Alendronate (2 mg/kg/weekly i.p.): 12 weeks | 0 days | 12 weeks | ALN ↓subchondral cortical bone thickness and BV/TV and tended to diminish cartilage damage. |
| Thomsen et al. [41] | Dunkin Hartley Guinea Pig Male 3 months old (56) | Spontaneously model: Naturally occurring Knee | Risedronate (30 μg/kg/five times a week s.c.): 6, 12, or 24 weeks | – | 0, 6, 12, or 24 weeks | RIS did not reduce the articular cartilage damage and did not influence on subchondral bone plate stiffness, but ↓ serum CTX-II. RIS treatment reduced bone resorption and bone formation. |
| Ding et al. [42] | Dunkin Hartley Guinea Pig Male 6.5 months old (66) | Spontaneously model: Naturally occurring Knee | Alendronate (10 or 50 μg/kg/twice weekly s.c.): 9 or 17 weeks | – | 9 or 17 weeks | ALN groups showed worse cartilage degeneration in spite of subchondral bone plate thickness, bone mineral content and density. |
| Dearmin et al. [43] | Mixed-breed | Surgically induced OA: Zoledronic acid (10 or 25 μg/kg/every 3 months s.c.): 12 | – | 0, 1, 6, 9, and 12 months | Serum, synovial and | ZOL high-dose group resulted in a chondroprotective effect |

**Knee compression therapy**: dosage, frequency and duration

**Knee induced OA**: sub-chronic: 28 to 35 days delayed chronic: day 21 to 35; sub-chronic: 28 to 35 days

**Knee ACLT induced OA**: surgically-placed ACLT and related OA

**Menopause OA occurring spontaneously**: 26 week old (FVB) Mice (FVB/NJ (B6) and C57BL/6)

**Zoledronic acid (ZOL)**: 10, 30, or 100 μg/kg/every third day s.c.

**Risedronate (RIS)**: 10 or 50 μg/kg/twice weekly s.c.

**Alendronate (ALN)**: 2 mg/kg/weekly s.c.

**Histology score of cartilage** (Mankin scoring system on safranin-O samples-CT): subchondral bone plate thickness, Tb.Th, Tb.Sp, and BS/BV. Bone density and mineral content.

**Histologic assessments (OARSI histology score of cartilage)**: subchondral bone volume (BV/TV), osteophytes, articular cartilage damage and osteophyte formation. Serum and urinary analyses (COMP, CTX-I, CTX-II) and osteophytes.

**Histologic analysis (Modified Mankin score system)**: subchondral bone volume (BV/TV) and osteophytes.

**Histology of cartilage and osteophyte** (Modified OARSI histological analysis (toluidine blue and TRAP stained samples)).

**Macroscopic evaluation and histological analysis (Modified Mankin score system)**: subchondral bone volume (BV/TV) and osteophytes.

**Histomorphometric assays**: subchondral bone volume (BV/TV), osteophyte area (dose-dependent manner). ↓MMP-13, MMP-9 and TGFβ.

**Serum analyses**: CTX-I and P1NP.

**Bone densitometry**: X-ray absorptiometry scanner (BMD). Histological analysis (toluidine blue and TRAP stained samples).

**Serum, synovial and subchondral bone samples**.

**Histology score of cartilage** (Mankin scoring system on safranin-O samples-CT): subchondral bone plate thickness, Tb.Th, Tb.Sp, and BS/BV. Bone density and mineral content.

**Histologic assessments (OARSI histochemistry (MMP-13, MMP-9, TGFβ))**: subchondral bone volume (BV/TV), osteophytes.

**Histologic assessments (OARSI and Mankin score system)**: subchondral bone volume (BV/TV), osteophytes.
Table 1: Characteristics of included preclinical studies (Continued)

| References       | Animal model (n) | OA model and site | Therapy: dosage, frequency and duration | Start point | Follow-up and evaluations | Main results |
|------------------|------------------|-------------------|-----------------------------------------|-------------|--------------------------|--------------|
| Pelletier et al. | Crossbred dog    | Surgically induced OA: ACLT Knee | Tiludronic acid (2 mg/kg on days 14, 28, 56 and 84 s.c.) + extracapsular stabilization surgery | 14 days     | 1 year                   | TLN-treated animals presented a reduction in the severity of macroscopic and histologic cartilage lesions and showed ↓MMP-1, MMP-3, and MMP-13 levels. |
| Moreau et al.    | Crossbred dog    | Surgically induced OA: ACLT Knee | Tiludronic acid (2 mg/kg/every two weeks s.c.) 6 weeks | 0 days      | 8 weeks                  | TLN treated animals having less joint effusion, lower synovitis score and a greater subchondral bone surface. ↓PGE2, NOX, MMP-13, camphein K and ADAMTSS. TLN failed to prevent or correct cartilage lesion and osteophyte development. |

ACLT anterior cruciate ligament transection, ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs, ALN Alendronate, BMD bone mineral density, BAP bone-specific alkaline phosphatase, BPs bisphosphonates, BMP bone morphogenic protein, BS/BV bone surface to bone volume ratio, BV/TV bone volume fraction, CACTC cyclic articular cartilage tibial compression, cCg.Th calcified cartilage thickness, COLX type-X collagen, Conn.D connectivity density, COMP cartilage oligomeric matrix protein, CS846 chondroitin sulfate 846, μCT micro-computed tomography, Cl.Th cortical thickness, CTX collagen crosscytometric terminal telopeptide, IFP insulin-like growth factor, IL interleukin, MCL medial collateral ligament, KTI knee triad Injury, MNA monosodium iodoacetate, MMP matrix metalloproteinase, MMT medial meniscectomy, MRI magnetic resonance imaging, NOX nitrates and nitrates, PCR polymerase chain reaction, OA osteoarthritis, OARSI Osteoarthritis Research Society International, OIX overoxidized, PAM pamidronate, PG prostaglandin, PNP procollagen type 1 N-terminal propeptide, RANKL receptor activator of nuclear factor-kappa B ligand, RIS risedronate, SB.Th subchondral bone thickness, SMI structural model index, Tb.N trabecular number, Tb.Pf trabecular bone pattern factor, Tb.S trabecular separation, Tb.Th trabecular thickness, TGF transforming growth factor, TRAP tartrate-resistant acid phosphatase, ZLN zoledronic acid, VEGF vascular endothelial growth factor, TLN tiludronate. *Start point: time between induced OA and treatment administration.

than half of the studies analyzed (6 out of 11) with only one negative effect, recorded in a guinea pig study [42], while risedronate treatment showed variable efficacy, with three articles classified as negative or no effect (3 out of 6) [26, 27, 41]. Regarding the subchondral bone evaluations, most were performed by histomorphometric analysis and imaging techniques. BP-based therapy exhibited greater periarticular bone conservation and quality, and only two studies showed unclear effects, one which used alendronate [39] and another which studied the risedronate efficacy [41]. The biochemical markers of OA were mostly analyzed in serum, urine samples, and immunohistochemical assays. Out of thirteen included publications, BP-based therapy had a positive effect in eleven of them. Only one study on alendronate showed contradictory results [32], and one focusing on zoledronic acid exhibited no significant differences against the control group [29]. As far as osteophyte development is concerned, BPs were not able to inhibit the osteophyogenesis in most cases (9 out of 11), and only alendronate therapy showed an inhibitory response in three of the studies analyzed [33, 35, 46]. Lastly, the synovial inflammation was evaluated only in four studies, two focusing on zoledronic acid [29, 36], one on risedronate [22], and another on tiludronate [45]. Overall, BP treatments seemed to lower synovitis scores showing a tendency toward anti-inflammatory effects.

Quality and risk of bias assessments

Quality assessments

Figure 2 summarizes the quality assessments of the preclinical studies based on the ARRIVE guidelines. The results showed that in most papers at items 9 “Housing and husbandry,” 14 “Baseline data,” 15 “Number analysed,” 17 “Adverse events,” and 20 “Funding,” an evident lack of information was observed, with 23.1%, 53.85%, 76.9%, 73.1%, and 42.3% of frequencies respectively classified as “not reported.” By contrast, items 1 “Title,” 3 “Background,” 4 “Objectives,” 6 “Study design,” 11 “Allocating animals to experimental groups,” 12 “Experimental
outcomes,” 13 “Statistical methods,” 16 “Outcomes and estimation,” and 19 “Generalisability/translation” were classified as “reported,” showing high percentages of completed items, with frequencies of 80.8%, 76.9%, 96.15%, 80.8%, 76.9%, 100%, 84.6%, 100%, and 92.3%. The remaining items, 2 “Abstract,” 5 “Ethical statement,” 7 “Experimental procedures,” 8 “Experimental animals,” 10 “Sample size,” and 18 “Interpretation/scientific implications,” were assigned as “unclear,” showed incomplete items or did not report any sub-items, with frequencies of 57.7%, 46.15%, 80.8%, 46.15%, 96.15%, and 69.2%.

Risk of bias

The graphical results of the risk of bias assessments in the included studies were shown in Fig. 3 using the SYRCLE tool. Generally, most of the items evaluated were assigned as “unclear risk of bias” showing frequencies above 50%. The higher risk of bias was observed at items 3 “Allocation concealment,” 5 “Blinding of caregivers and/or investigators,” 6 “Random outcome assessment,” and 10 “Other sources of bias,” with frequencies of 30.8%, 26.9%, 23.1%, and 23.1%, respectively. By contrast, the lower risk of bias was assigned at items 2 “Baseline characteristics,” 7 “Blinding of outcome assessor,” and 9 “Selective outcome reporting,” with frequencies of 65.4%, 61.5%, and 73.1%.

Discussion

The aim of this systematic review was to study the effect of bisphosphonates in osteoarthritic experimental animal models. In this study, a total of 26 publications with 5 different types of BPs were selected in order to elucidate whether these antiresorptive therapies could somehow influence the OA progression. To the best of our knowledge, no previous systematic reviews have evaluated their effect on synovial joint tissues and biochemical markers in preclinical models. However, a literature review analyzing the uses of BPs as a treatment modality in OA preclinical and clinical studies has been recently published concluding that there are some appreciable discrepancies between them [47]. Regarding human studies, we only identified one meta-analysis which examined the efficacy of BPs in the treatment of OA pain in humans [15] and other two which analyzed the effects of BPs compared with placebo in terms of clinical and structural outcomes in specific human knee OA [13, 14]. Even though their main results did not seem to be very promising, some of them suggested that their administration in specific patients with high rates of subchondral bone turnover may be beneficial [13, 14]. Although in some cases translating preclinical findings into clinical management of OA may not be highly reliable, animal preclinical models may provide an excellent opportunity to evaluate the direct effect of different therapies on affected joints [48]. In this review, the most

### Table 2: Therapy duration of bisphosphonates

| Animal model | Short-term (≤2 months) | Intermediate-term (2 to 6 months) | Long term (≥6 months) |
|--------------|-----------------------|----------------------------------|----------------------|
|              | Reference Drug Duration | Reference Drug Duration | Reference Drug Duration |
| Rabbit       | She et al. [20] ZLN * | Shirai et al. [23] ALN 3 |                      |
|              | Lamproploulou et al. [21] ZLN 1 |                      |                      |
|              | Permuy et al. [22] RIS 2 |                      |                      |
|              | Zhang et al. [24] ALN 2 |                      |                      |
|              | MacNeil et al. [25] RIS 1.5 |                      |                      |
|              | Doschack et al. [26] RIS 1.5 |                      |                      |
|              | Doschack et al. [27] RIS 1.5 |                      |                      |
|              | Muehlemann et al. [28] ZLN 2 |                      |                      |
| Rat          | Cinari et al. [29] ZLN 1.5 | Bagi et al. [30] ZLN 2.5 |                      |
|              | Mohan et al. [32] ALN < 1 | Zhu et al. [31] ALN 4.5 |                      |
|              | Panahafir et al. [33] ALN 2 | Hayami et al. [37] ALN 2.5 |                      |
|              | Koh et al. [34] PAM 2 |                      |                      |
|              | Strassle et al. [36] ZLN < 1 |                      |                      |
|              | Jones et al. [35] ALN/RIS 2 |                      |                      |
| Mice         | Adebayo et al. [38] ALN 1.5 | Snickers et al. [40] ALN 3 |                      |
|              | Khorasani et al. [39] ALN 1 |                      |                      |
| Guinea-Pig   |            | Ding et al. [42] ALN 4.5 |                      |
|              | Moreau et al. [45] TLN 1.5 | Pelletier et al. [44] TLN 3 |                      |
| Dog          |            |                        |                      |

ALN alendronate, PAM pamidronate, RIS risedronate, ZLN zoledronic acid, TL tiludronate. Duration in months. *Only once post-surgery
commonly used animal models were rabbits and rats. Among their main advantages, one should point out their easy management and low maintenance costs, surgeries are easier to perform than in smaller animals such as mice, complete genomes are available from study, and both are useful in studying the efficacy of compounds [49]. Other animal models as mice, guinea pigs, and dogs were also included in this study. It is important to highlight that the variety of animal species and the different models of OA could make direct comparison among studies challenging. Moreover, it is important to underline that no single animal model is able to mirror all variants and aspects of OA. Therefore, depending on our experimental goal, appropriate animal model should be chosen [12].

Among the main advantages, one should point out their easy management and low maintenance costs, surgeries are easier to perform than in smaller animals such as mice, complete genomes are available from study, and both are useful in studying the efficacy of compounds [49]. Other animal models as mice, guinea pigs, and dogs were also included in this study. It is important to highlight that the variety of animal species and the different models of OA could make direct comparison among studies challenging. Moreover, it is important to underline that no single animal model is able to mirror all variants and aspects of OA. Therefore, depending on our experimental goal, appropriate animal model should be chosen [12].

More than half of the publications included in this study were surgically induced models (n = 16), in which ACLT (n = 10) was the most used surgery technique. This was followed by chemically induced models (n = 5) which received an injection of MIA, by spontaneous models due to naturally occurring OA (n = 3) and finally, by non-invasive loading models (n = 2). These findings slightly differ to those described by other authors of OA preclinical studies. Half of these used spontaneous models, followed by surgical induction models and chemically induced models [50].

In addition to the different animal model used, various experimental protocols were reported in relation to the type of bisphosphonate, the posology, and the route of administration. Another major concern with BPs is that the bioavailability may be different in relation to the animal species under study, so it should be taken into account when the experiment is designed [24]. Besides, there are also notable differences among the duration and the baseline of therapy. Consequently, comparing findings in order to draw significant conclusions about the drug efficacy is challenging.
Regarding the therapy duration, we observed in the studies that currently there is a lack of evidence to evaluate their efficacy as disease-modifying drugs on the long-term. As we could observe in this review, there are almost literally no studies that evaluated the bisphosphonate effect after 6 months of treatment. In this context, we should take into account that the long-term bisphosphonate pharmacological response in preclinical studies is basically unknown. It is possible that the initial chondroprotective effect observed in some publications could not be sustained over time. Interestingly, in one of the included studies, the alendronate use was analyzed comparing different treatment durations (7, 14, or 56 days). Although all of them were based on short periods of time, differences were already observed and, in spite of a positive initial response, alendronate use was not able to mitigate the long-term OA progression [39]. Similarly, another study using guinea pigs as animal model exposed that risedronate did not have the ability to prevent articular cartilage damage after 6 months of treatment [41]. On the contrary, Dearmin et al. determined the zoledronic acid effect in a dog experimental model for a year, showing a beneficial response with less articular damage and fewer biomarkers changes [43].
Regarding clinical studies, an interesting human trial conducted for 2 years, concluded that risedronate did not have the ability to reduce the OA evolution. However, reduced cartilage degradation markers were detected [51]. Another 2-year clinical trial on hip OA showed that osteoporosis-standard dosing of alendronate (35 mg/week) did not demonstrate an evident disease-modifying effect, but decreased clinical pain and showed lower C-telopeptide fragments of type II collagen (CTX-II) levels [52]. According to this, it is interesting to observe that for an optimal response on cartilage protection, higher BP doses than those used to treat osteoporosis may be required. Among the studies included in this review, 5 out of 26 publications studied the efficacy of these therapies at different doses. Generally, they concluded that BPs seemed to reduce the osteoarthritic changes in a dose-dependent manner showing better chondroprotective effects at high doses [20, 36, 37, 39, 43].

Another point of interest is the treatment timing initiation in relation to OA stage. It has been observed that pre-emptive and early BPs therapies may lead to improved outcomes. By contrary, delayed treatments have been associated with reduced chondroprotective efficacy. In this case, 3 experimental studies evaluated the alendronate or zoledronic acid effects on cartilage degradation and subchondral bone quality at various points of OA stage [31, 32, 36]. Although certain positive effects were observed on the subchondral bone, independently of the time point of treatment initiation, an obvious time-dependent efficacy was detected on cartilage status. As proposed by Strassle et al., these findings may partially explain the differences in outcomes observed between clinically and preclinically studies. Given that some positive findings reported in experimental studies could be related to initial uses of BPs in early stages of OA, while in clinical trials, therapies are usually initiated when the disease is advanced [36]. For this reasons, we can conclude that the stage of disease when treatments are employed is a key factor in the effectiveness of the antiresorptive therapies.

Among this high experimental variability, it is extremely difficult to draw specific conclusions regarding the effectiveness of BPs. Generally, in this review, we noted that antiresorptive administration seemed to show positive subchondral bone conservation and fewer biomarker alterations. However, they did not appear to suppress the osteophyte formation. Regarding the cartilage status, the observed effects of BPs varied among the studies but overall, zoledronic acid exhibited the greatest chondroprotective response [20, 21, 28, 29, 36, 43]. Additionally, there is no consensus on which are the most adequate methods of evaluation. As previously discussed, the parameters most commonly assessed in the preclinical studies analyzed herein were the cartilage degradation and the subchondral bone changes. It is well known that the osteoarthritis pathology involves all tissues included in the synovial joint. Moreover, synovitis has been correlated with the progression of the OA and it is the main cause of pain [53]. However, only 4 publications in this systematic review focused on the synovial inflammation [22, 29, 36, 45]. Considering that antiresorptive therapies appear to show a positive anti-inflammatory effect, further studies, including on the evaluation of the synovial membrane status, are needed in order clarify its role in the pathophysiology of the disease.

Regarding the quality evaluation of the preclinical animal studies included in this review, most of the publications showed quite well reported items. Nevertheless, there were several key items that we identified as poorly reported, similarly to what was observed in other reviews of preclinical OA studies [50]. Half of the publications included showed incomplete ethical statements with lack of information in relation to animal care guidelines. Besides, the majority of studies did not provide precise details about anesthesia and analgesia protocols, the method of euthanasia, or further relevant information such as the source of animals. Incomplete details about housing and husbandry were reported in almost half of the studies. In terms of sample size, only one study explained how the number of animals was arrived at [38]. This observation coincided with that observed in other systematic review with animal studies in rheumatology, since this item was not reported in any paper [54]. Additionally, we observed an important lack of details such as the health status description, the absolute number of animals included, and the description of adverse events, once more in agreement with Ting et al. In relation to assessments of risk of bias, as reported in other systematic reviews with animal studies, we observed an appropriate description of baseline characteristics and selective outcome reporting [55]. The same applied to the blinding of outcome assessor [50]. By contrast, a higher risk of bias was identified at allocation concealment, the randomly housed animals during the experiment, and the blinding of caregivers [55]. Additionally, many entries had to be judged as “unclear risk of bias” showing that some research publications on animals fail to report important information. An interesting previous survey research of 271 animals studies revealed that reported experimental details on animals, methods, and materials continue to be very poor [56]. According to this, we consider improving the reporting quality of essential details in experimental animal studies is essential [19].

Our study has several limitations to consider. One of them is that this study did not include a meta-analysis.
Another limitation is the great heterogeneity in the variables of the experimental studies, which make comparisons among publications challenging. Additionally, the quality and methodology of the experimental animal studies was highly variable.

Conclusions
Bisphosphonates have been proposed as possible disease-modifying drugs in OA, but as far as published preclinical studies are concerned, they show a great heterogeneity in their outcomes. Additionally, the evidence of their efficacy is poor and, at present, hardly any long-term studies have been conducted. In this review, significant differences were observed in the experimental designs, including the variety of OA animal models and the drug type, duration, and posology. Consequently, it is extremely difficult to draw specific conclusions about the effectiveness of these drugs. However, the results of this systematic review suggested that the type of dose selected and the time point of treatment initiation may be two key factors in the effectiveness of these therapies, highlighting better chondroprotective effects at high doses and pre-emptive administrations. Regarding the therapy duration, long-term studies are needed to elucidate the effect of BPs over time. Additionally, we noted that antiresorptive administration seemed to improve the subchondral bone quality and show fewer biomarker alterations. However, they did not appear to suppress the osteophyte development and their chondroprotective effect is highly variable among the studies. Lastly, with reference to synovial membrane evaluation, bisphosphonate treatments seemed to show a tendency toward anti-inflammatory effect but further studies are needed in order to clarify their effectiveness.

Abbreviations
ACLT: Anterior cruciate ligament transaction; ALN: Alendronate; ARRIVE: Animals in Research Reporting In Vivo Experiments; BPs: Bisphosphonates; CTX-II: C-telopeptide fragments of type II collagen; KTI: Knee triad injury; MIA: Monosodium iodoacetate; MMT: Medial meniscectomy; OA: Osteoarthritis; PAM: Pamidronate; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RIS: Risedronate; SYRCLE: Systematic Review Centre for Laboratory animal Experimentation; TIL: Tildronate; WOS: Web of Science; ZOL: Zoledronic acid

Acknowledgements
S.F.-M. acknowledges the FPU programme for her pre-doctoral contract (Ref. FPU15/05325) form Spanish Government. Ministerio de Ciencia, Innovación y Universidades.

Authors’ contributions
SFM have been involved in the literature search, data extraction, and interpretation and drafted the manuscript. FM and MP contributed substantially to the study conceptions and design. MLP and AGC participated in the analysis interpretation and critically revised the manuscript. The authors read and approved the final manuscript.

Funding
This research received no external funding.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Received: 23 September 2020 Accepted: 11 February 2021
Published online: 22 February 2021

References
1. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum. 2004;50:341–4.
2. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol. 2014;28:5–15 Bailliere Tindall Ltd.
3. Nelson AE. Osteoarthritis year in review 2017; clinical. Osteoarthr Cartil. 2018; 26:319–25 W.B. Saunders Ltd.
4. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abate-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211–59 Lancet Publishing Group.
5. Aagot C, Hofmeister EH, Budsberg SC. Systematic review of clinical trials of treatments for osteoarthritis in dogs. Javma. 2007;230:514–21.
6. Anderson KL, O’Neill DG, Bredbelt DC, Church DB, Mesenec RL, Sargan D, et al. Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8:1–12 Nature Publishing Group.
7. Henrotin Y, Sanchez C, Balliagand M. Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives. Vet J. 2005;170:113–23.
8. Cañeteda S, Roman-Blas JA, Largo R, Hemero-Beaumont G. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol. 2012;83:315–23 Elsevier Inc.
9. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230–7.
10. Buckland-Wright CJ, Messent EA, Bingham CO, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology. 2007;46:257–64.
11. Kuyuni EL, Narayan, G, Nair LS, Laurencin CT. Animal models of osteoarthritis: classification, update, and measurement of outcomes. J Orthop Surg Res. 2016;11:1–27.
12. Poole R, Blake S, Buschmann M, Goldring S, Laverty S, Lockwood S, et al. Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthr Cartil. 2010;18:510–6 Elsevier.
13. Vaysbrot EE, Osani MC, Musetti MC, McAlinden TE, Bannuru RR. Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2018;26:154–64.
14. Deveza LA, Bierna-Zeinstra SMA, Event Van Spil W, Oo WM, Saragiotto BT, Neogi T, et al. Efficacy of bisphosphonates in specific knee osteoarthritis subpopulations: protocol for an OA Trial Bank systematic review and individual patient data meta-analysis. BMJ Open. 2018;8:23889.
15. Davis AJ, Smith TO, Hing CB, Sofiat N. Are bisphosphonates effective in the treatment of osteoarthritis pain? A Meta-Analysys and Systematic Review. PLoS One. 2013;8:72714.
16. Moher D, Liberat A, Tetzlaff J, Altman DG. Preferred reporting items for systematic review and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41 Elsevier.
17. Liberat A, Altman DG, Tetzlaff J, Mulrow C, Gatzschke PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1–34 Public Library of Science.
